Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ(R) Data Driving Treatment Interventions at 2025 ASH Annual Meeting
(NASDAQ:ADPT), SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of its clonoSEQ(R) test among the 90 abstracts featuring clonoSEQ data at the 67th […]